"Horizon’s [now part of Revvity] CHOSOURCE cell line combined with our own vector technology is a robust platform for generating high protein expression stable cell lines to support our antibody product development through commercial manufacturing. We are pleased with current program results and move to further collaborate with Horizon Discovery group [now part of Revvity group]." Read moreDr. Dou Changlin
R&D President and COO
Boan Biotech
"Since implementing the CHOSOURCE CHO-K1 knockout cell line in our drug development workflow in March 2019, we have been able to hit the ground running and develop this mAb drug candidate against different diseases including the first in-human mAb in phase I trial in Australia against tetanus toxin. These efforts have shown how easy and effective the Horizon [now part of Revvity] cell line was to implement and adapt to our processes. We are pleased with the results and continue to build our drug pipeline using the CHOSOURCE CHO-K1 cell line." Read more
Trinomab Biotech
"We are delighted to partner with Revvity to provide our customers a state-of-the-art GS expression platform with a track record of success which complements Celonic’s early phase offering. We are committed to bringing our customers of all sizes, expertise, agility, and solutions to develop and manufacture life-improving drugs effectively and efficiently." Read more
Dr. Samanta Cimitan
CEO
Celonic Group
Revvity’s bioproduction offering
Revvity's Bioproduction unit is dedicated to empowering businesses across the global biotherapeutic landscape. With over 100 global licensees, ranging from academia to large pharma and biotech, as well as small to large CDMOs, we serve as the catalyst, helping our diverse partners to unlock their full potential. Our solutions are tailored to meet the unique needs of each customer, offering licensing terms fitted to their requirements.
For more information on the CHOSOURCE expression platform and how we can support your biotherapeutic development click here.